Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study (Q43694841)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2008

Language	Label	Description	Also known as
English	Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study	scientific article published in September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

methicillin-resistant Staphylococcus aureus

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

I Florescu

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Beuran

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

R Dimov

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Razbadauskas

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Bochan

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

G Fichev

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

G Dukart

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

T Babinchak

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C A Cooper

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

E J Ellis-Grosse

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

N Dartois

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

H Gandjini

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

307 Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

62 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

i17-28

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Current and emerging serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic resistance in Gram-positive cocci.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Life-threatening community-acquired methicillin-resistant Staphylococcus aureus infection in Australia.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Vancomycin-resistant enterococci: colonization, infection, detection, and treatment

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Treatment options for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Impact of antibiotic resistance on clinical outcomes and the cost of care

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline: a novel glycylcycline antibiotic

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline for the treatment of infections due to resistant Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Overview of resistant gram-positive pathogens in the surgical patient

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic resistance in the intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial ag

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an International Surveillance Programme. SENTRY Participants Group.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

A practical guide to the treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Complicated infections of skin and skin structures: when the infection is more than skin deep

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTR

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Antibiotic-resistant enterococci and the changing face of surgical infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Efficacy of linezolid versus comparator therapies in Gram-positive infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Daptomycin: the first approved lipopeptide antimicrobial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Tigecycline: a first in class glycylcycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN250

21 January 2018

Identifiers

10.1093/JAC/DKN250

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43694841&oldid=2102635185"